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Comprehensive sequencing of human cancers has identified recurrent mutations in genes encoding chromatin regulatory
proteins. For clear cell renal cell carcinoma (ccRCC), three of the five commonly mutated genes encode the chromatin
regulators PBRM1, SETD2, and BAP1. How these mutations alter the chromatin landscape and transcriptional program in
ccRCC or other cancers is not understood. Here, we identified alterations in chromatin organization and transcript
profiles associated with mutations in chromatin regulators in a large cohort of primary human kidney tumors. By as-
sociating variation in chromatin organization with mutations in SETD2, which encodes the enzyme responsible for
H3K36 trimethylation, we found that changes in chromatin accessibility occurred primarily within actively transcribed
genes. This increase in chromatin accessibility was linked with widespread alterations in RNA processing, including intron
retention and aberrant splicing, affecting ~25% of all expressed genes. Furthermore, decreased nucleosome occupancy
proximal to misspliced exons was observed in tumors lacking H3K36me3. These results directly link mutations in SETD2 to
chromatin accessibility changes and RNA processing defects in cancer. Detecting the functional consequences of specific
mutations in chromatin regulatory proteins in primary human samples could ultimately inform the therapeutic application
of an emerging class of chromatin-targeted compounds.
[Supplemental material is available for this article.]
Large-scale cancer sequencing studies continue to identify muta-
tions in genes encoding chromatin regulatory proteins in a wide
variety of human cancers. The downstream molecular conse-
quences of these mutations, however, remain unknown. Clear cell
renal cell carcinoma (ccRCC) is a particularly relevant model for
the study of chromatin regulation in cancer for several reasons.
First, relative to mutations in other classes of genes, ccRCCs are
marked by frequent mutation of chromatin regulators (Dalgliesh
et al. 2010; Varela et al. 2011; Pena-Llopis et al. 2012; Ryan and
Bernstein 2012). Three of the more commonly mutated genes in
ccRCC include chromatin modifiers SETD2, PBRM1, and BAP1
(Dalgliesh et al. 2010; Varela et al. 2011; Pena-Llopis et al. 2012;
Kapur et al. 2013), suggesting that alterations at the level of chro-
matin may play a prominent role in the development of ccRCC
(Dalgliesh et al. 2010; Varela et al. 2011). Mutation-associated
changes in chromatin organization may promote oncogenesis
in novel ways, and it has been suggested that specific chromatin
regulator mutations may confer differences in patient survival or
associate with more advanced disease (Hakimi et al. 2012). How-
ever, the downstream effect of these mutations on tumor chro-
matin biology remains unknown. Second, this cancer is tightly
associated with a distinct transcriptional program resulting from
the inactivation of the von Hippel–Lindau (VHL) tumor suppressor
gene (Kim and Kaelin 2004; Bratslavsky et al. 2007; Nickerson et al.
2008; Jonasch et al. 2012). The loss of VHL results in the stabiliza-
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tion of hypoxia inducible factors (HIFs), transcription factors that
activate a complex program of downstream targets, including vas-
cular endothelial growth factor (VEGF) and other genes (Gordan
et al. 2008; Gore and Larkin 2011; Jonasch et al. 2012). Third,
besides VHL and chromatin regulators, mutations in other cancer-
associated pathways are generally absent from ccRCC tumors.
Elucidating the functional consequences of mutations in
genes encoding chromatin regulatory proteins on chromatin or-
ganization and transcription in human tumor specimens requires
the application of techniques developed for cultured cells to pri-
mary human tissues. Formaldehyde-assisted isolation of regulatory
elements (FAIRE) interrogates chromatin accessibility by isolating
nucleosome-depleted regions of DNA (Nagy et al. 2003; Hogan
et al. 2006; Giresi et al. 2007; Giresi and Lieb 2009; Simon et al.
2012). These regions harbor regulatory elements such as active
transcriptional start sites, transcriptional enhancers, insulators,
silencers, and locus control regions (Hogan et al. 2006; Giresi et al.
2007; Giresi and Lieb 2009; Gaulton et al. 2010; Song et al. 2011;
Simon et al. 2012). As a component of the ENCODE Project, FAIRE
has been used to identify regulatory elements across a wide range
of cell lines (Song et al. 2011; Thurman et al. 2012). However, the
application of FAIRE to primary human tissue or to explore the
association between chromatin and genetic alterations in cancer
has yet to be evaluated.
We modified FAIRE for use on primary human clinical sam-
ples to define the chromatin landscape in a large cohort of ccRCC
tumors and matched normal tissues. We identified tumor- and
normal-kidney-specific classes of chromatin accessibility changes,
as well as those associated with chromatin modifier mutations. We
focused our study on SETD2, which trimethylates lysine-36 on
histone H3 (H3K36me3) (Rayasam et al. 2003; Sun et al. 2005;
Brown et al. 2006; Edmunds et al. 2008; Yoh et al. 2008; Duns et al.
2010). Associated with the RNA polymerase II complex, SETD2-
dependent methylation tends to occur toward the 39 ends of genes
and over nucleosomes located at exons (Edmunds et al. 2008;
Kolasinska-Zwierz et al. 2009; Schwartz et al. 2009). SETD2 and
H3K36me3 seem to play a role in cotranscriptional RNA process-
ing. In cell-culture-based studies, silencing of SETD2 or readers of
H3K36me3 has been associated with differential exon inclusion
for individual genes (Luco et al. 2010; Pradeepa et al. 2012) and
alternative transcription start site utilization (Carvalho et al. 2013).
However, the consequence of SETD2 deficiency on chromatin
organization and RNA processing remains to be explored on a ge-
nome-wide scale and in a disease-relevant model. SETD2 is mu-
tated in ;12% of primary human ccRCC tumors and results in
H3K36me3 deficiency (Gerlinger et al. 2012). A similar rate of
SETD2 mutation has also been observed in high-grade gliomas
(Fontebasso et al. 2013). A recent study of intratumor heteroge-
neity in ccRCC identified distinct SETD2 mutations in all sub-
sections of the same tumor suggesting the importance of disrupt-
ing SETD2 function for a subset of tumors (Gerlinger et al. 2012).
We found that SETD2 mutation was associated with chro-
matin accessibility differences preferentially in gene bodies, and
these genes frequently exhibited RNA processing defects. Nearly
25% of all expressed genes demonstrated aberrancies in splicing,
including exon skipping, intron retention, and alternative tran-
scription start and termination sites. We observed that misspliced
exons were marked by a striking increase in chromatin accessibility
immediately upstream of the aberrant splice and a loss of nucleo-
some occupancy directly over the exon. This study represents
the first investigation of chromatin organization in human tumors
to identify the impact of chromatin modifier mutations on the
genomic landscape. Understanding chromatin dysregulation in
cancer may ultimately inform the application of emerging classes
of chromatin-targeted small molecules in renal cancer.
Results
Differences in chromatin accessibility between tumors
and normal kidney tissue corroborate the underlying
role of HIF in ccRCC
We performed FAIRE-seq on 42 primary ccRCC tumor samples as
well as uninvolved matched normal kidney from seven of these
patients (Supplemental Fig. S1A,B). We identified about 11,000
500-bp genomic intervals with differences in chromatin accessi-
bility that discriminated tumors from normal kidney (two-sided
t-test, P < 0.01) (Fig. 1A,B). For ;70% of these regions, FAIRE signal
was increased in the tumor samples, indicative of nucleosome
depletion. Using hierarchical clustering, three clusters of genomic
loci emerged: Two were marked by tumor-specific nucleosome
depletion (Clusters 1 and 2), and another was characterized by
nucleosome depletion in normal kidney tissue but not in tumors
(Cluster 3). Virtually all tumors exhibited nucleosome depletion at
the sites in Cluster 1, whereas ;50% of tumors demonstrated
FAIRE enrichment at regions in Cluster 2.
We then examined each cluster for shared biological associ-
ations among the loci and adjacent genes. Regions in each cluster
were associated with genes (GREAT) (McLean et al. 2010)). For sites
in Cluster 1, 2274 genes were identified, many of which were
members of several cancer-associated gene sets. Particularly in-
teresting in the setting of ccRCC, where HIF transcription factor
family stabilization and activation of hypoxia response genes is a
central feature of this tumor type, we found that the most signif-
icantly associated genes in this cluster were involved in HIF activa-
tion and hypoxia regulation (Fig. 1C; full list of associations for each
cluster in Supplemental Fig. S2). This association was not observed
for regions in Cluster 2 or 3 (Supplemental Fig. S2). Analysis of the
sequences in Cluster 1 identified several highly enriched transcrip-
tion factor (TF) motifs (Heinz et al. 2010), including the hypoxia
response element consensus binding sequence (Fig. 1D). We addi-
tionally found that previously identified HIF1A and HIF2A (EPAS1)
binding sites (Schodel et al. 2011) only significantly overlapped loci
in Cluster 1 (P < 0.001) (Fig. 1B,E). The detection of features associ-
ated with the hypoxia response through variation in chromatin
accessibility is consistent with the unique link between HIF activity
and ccRCC, and these results demonstrate the ability of FAIRE to
detect central biological pathways through the identification varia-
tions in chromatin organization in an unbiased fashion.
SETD2 mutations link H3K36me3 loss with changes
in chromatin accessibility
To identify mutations in chromatin modifiers within tumor sam-
ples, we genotyped 33 unique ccRCC tumors (from our cohort of
42 above) and the same seven matched normal kidney specimens
(Supplemental Fig. S1A,B). We classified sequence variants based
on predicted ability to confer severe protein structural changes,
including frameshift, nonsense, and mutations altering an anno-
tated splice site (‘‘high severity’’), as well as missense mutations
(‘‘moderate severity’’) (Fig. 2A). Approximately half of the SETD2
mutations in these classes were predicted to disrupt the catalytic
SET domain. High- and moderate-severity mutations were also




which mediates the interaction with RNA polymerase II. A pre-
diction of copy number using the genotyping data also revealed
that with the exception of one tumor (which displayed one high-
and one moderate-severity mutation) loss of heterozygosity co-
incided with mutations in SETD2 (Supplemental Fig. S4C).
We identified about 7000 500-bp windows exhibiting signif-
icant variation in FAIRE enrichment between SETD2-mutant and
SETD2-normal tumors (two-sided t-test, P < 0.01) (Fig. 2B; Sup-
plemental Fig. S1C). In the SETD2-mutant tumors, FAIRE signal at
these regions was most commonly increased (80%), suggesting
that SETD2 loss is preferentially associated with greater chromatin
accessibility. SETD2 trimethylates H3K36 typically at gene bodies
(Barski et al. 2007; Kolasinska-Zwierz et al. 2009). Regions with
increased FAIRE signal in SETD2-mutated tumors (one-sided t-test,
Figure 1. Regions of tumor-specific nucleosome eviction identify the underlying role of HIF in ccRCC. (A) Hierarchical clustering of median-centered
FAIRE signal in windows with significant differences between tumors and normal kidney (two-sided t-test, P < 0.01). (B) FAIRE-seq tracks for ccRCC (black)
and uninvolved kidney (red) at two loci. (Blue) ChIP-seq signals (Schodel et al. 2011) from HIF1A, HIF2A, and ARNT. (C ) The top five Gene Ontology
associations (q < 1 3 105) with sites in Cluster 1 are shown. (D) Transcription factor binding motifs enriched in Cluster 1 compared with local background
500-bp flanking windows (>2.5-fold over background and present in at least 10% of the Cluster 1 windows). P-values relative to local background are
shown. (E) Fraction of HIF1A and HIF2A binding sites (Schodel et al. 2011) that overlap the loci in Clusters 1, 2, and 3 compared with permuted controls.
Errors bars represent standard deviation (SD).
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P < 0.01) also overlapped gene bodies (49% of sites), most of which
(91%) were marked by H3K36me3 in normal kidney (P < 0.001
relative to permuted control). More specifically, regions of in-
creased chromatin accessibility associated with SETD2 mutation
were enriched directly over the same domains marked by H3K36me3
(24.5%, P < 0.001 relative to permuted control) (Fig. 2C). In contrast,
the regions with decreased FAIRE signal showed no association
with H3K36me3 and, in fact, showed a significant underrep-
resentation relative to permuted control (P < 0.001). As an addi-
tional control, we tested for this association at regions with in-
creased FAIRE signal in PBRM1-mutant
tumors, which we expected to yield a di-
vergent set of loci. Indeed, areas of in-
creased chromatin accessibility associated
with this mutation were significantly un-
derrepresented at H3K36me3-marked re-
gions (P < 0.001 relative to permuted
control). Together, these data indicate
that regions of nucleosome depletion as-
sociated with SETD2 mutation preferen-
tially occur at genic sites normally marked
by H3K36me3.
Although SETD2 is responsible for
trimethylation of H3K36, other mecha-
nisms may influence H3K36 methylation
status. Moreover, the effects of specific
classes of SETD2 mutations in human
tumors on H3K36 methylation in RCC
are not known. We quantified H3K36me3
on a tissue microarray (69 tumors, 11
matched normal kidneys) (Fig. 2D; Sup-
plemental Fig. S1B). Whereas normal
kidney samples demonstrated consistent
nuclear H3K36me3 signal (Fig. 2E), tu-
mors displayed a range of staining in-
tensity, with 53% of tumors exhibiting
reduced H3K36me3 intensity. Hereafter,
this group of tumors is referred to as
‘‘H3K36me3 deficient.’’ Each of the eight
tumors that contained mutations pre-
dicted to affect SETD2 activity and screened
by IHC demonstrated H3K36me3 de-
ficiency (Fig. 2E). Tumors containing
mutations before the SET domain (Q320fs,
E978*, and Q1409*) displayed a complete
loss of H3K36me3 signal. However, tumors
with SETD2 mutations located within
the SET domain (G1681fs) or in the SRI
domain (R2510L) displayed reduced
H3K36me3 signal, suggesting that some
mutations may cause a partial loss of
function. Several tumors (eight of 13)
without identified SETD2 mutations also
exhibited reduced H3K36me3 signal.
SETD2 was undetectable by immuno-
histochemistry in two of these tumors,
whereas others exhibited decreased SETD2
mRNA, suggesting alternate mechanisms
for H3K36me3 loss (Supplemental Fig. S4).
We also observed evidence for SETD2
gene hemizygosity in other H3K36me3-
deficient SETD2-normal tumors, suggest-
ing that loss of heterozygosity may contribute to deficiency
in H3K36 methylating activity (Supplemental Fig. S4C). Inter-
estingly, one tumor (Tumor 25 in Supplemental Fig. S4C) did not
exhibit a copy number loss, carried two SETD2 mutations (E1846*,
high severity; I2499S, moderate severity), and showed a moderate
H3K36me3 deficiency (an intensity value of 0.36 in Fig. 2E). We
would thus predict that at least one of these mutations is hypo-
morphic, thus explaining the intermediate magnitude of the
H3K36me3 deficiency. Similarly, we detected two mutations in
SETD2 in another tumor (Tumor 3 in Supplemental Fig. S4C),
Figure 2. SETD2 mutations link H3K36me3 loss with changes in chromatin accessibility. (A) Sche-
matic representation of SETD2 mutations predicted to have high or moderate severity on protein
structure. (B) Hierarchical clustering of median-centered FAIRE signal in windows with significant dif-
ferences between SETD2 mutant tumors (red) and tumors without SETD2 mutation (gray) (2-sided
t-test, P < 0.01). (White) Samples not genotyped. (C ) Proportions of nucleosome-depleted loci over-
lapping H3K36me3-marked regions compared with loci with permuted genomic coordinates. Error bars
represent SD. (D) Representative immunostaining of two ccRCC tumor-normal pairs on the tissue
microarray. (E) Quantification of H3-normalized H3K36me3 intensity across 11 normal kidney and 69
renal tumors. Mutation severity (high, red; moderate, green; none, blue) is indicated. (White) Samples
with unknown SETD2 mutation status. The threshold for H3K36me3 deficiency was set to the lowest




which exhibited a global loss in H3K36me3 staining along with
copy number loss. These data suggest that either the tumor cell
population was heterogeneous and the remaining allele was differ-
entially mutated in each population (as was observed in Gerlinger
et al. 2012) or that the one remaining allele was mutated in two
locations. Together, these data illustrate that defective H3K36me3
is a common feature of ccRCC and that the SETD2 genotype alone
underestimates H3K36me3 deficiency.
SETD2 mutation is associated with DNA hypomethylation
proximal to sites of nucleosome depletion
In many higher eukaryotes, the H3K36me3 mark is recognized by
several chromatin readers, one of which is the PWWP domain of
the DNA methyltransferase DNMT3A, resulting in DNA methyla-
tion proximal to the marked histone (Dhayalan et al. 2010). Using
ccRCC DNA methylation data from The Cancer Genome Atlas
(TCGA), we observed localized changes (P < 0.05) in DNA meth-
ylation, primarily (>70% of probes) DNA
hypomethylation, in SETD2-mutant tu-
mors of the TCGA data set at nucleo-
some-depleted regions identified in our
SETD2-mutant tumors (Supplemental
Fig. S5). These data link changes in DNA
methylation to sites of nucleosome evic-
tion and/or loss of H3K36me3 through
SETD2 mutation. This result underscores
the importance of H3K36me3 and how
its loss may confer a multifaceted alter-
ation in the epigenome.
Intron retention and splicing defects
affect a large fraction of genes
with altered chromatin accessibility
in SETD2 mutant tumors
H3K36me3 has been previously impli-
cated in RNA processing (Luco et al. 2010;
de Almeida et al. 2011; Pradeepa et al.
2012), an association not previously ex-
amined in primary tissues or in a disease-
relevant model. We thus hypothesized
that H3K36me3 deficiency would alter
RNA processing and splicing in tumors
specifically at genes with altered chromatin
accessibility. To assess total RNA, including
pre-mRNA and nonpolyadenylated tran-
scripts, we performed RNA-seq on ribo-
some-depleted RNA from 33 tumors, all
but one of which was annotated with
mutational status (Fig. 2; Supplemental
Fig. S1); six tumors without H3K36me3
status assessed by immunohistochemistry
were omitted. We observed that H3K36me3-
deficient tumors displayed a striking en-
richment of intronic pre-mRNA signal
compared with tumors with normal
H3K36me3 levels. To quantify this effect,
we calculated intron retention scores
(IRS), which reflect the ratio of intronic to
exonic RNA-seq reads on a gene-by-gene
basis for each tumor. IRS values range
from 0 to 1, where a score of 0 represents a completely spliced
message and a score of 1 represents uniform genic coverage. Intron
retention was dramatically increased in the H3K36me3-deficient
tumors at 95% of the transcripts (6551 in total) marked by
H3K36me3 in normal kidney and by nucleosome depletion (one-
sided t-test, P < 0.01) in H3K36me3-deficient tumors (Fig. 3A,C;
Supplemental Figs. S1B, S6A, S7). To confirm this result, we per-
formed ChIP-seq from an independent normal kidney sample
(Supplemental Fig. S6B). Of the 6551 transcripts initially identified
(Fig. 3A; Supplemental Fig. S1), 6101 were identified using the
second normal kidney sample, representing a 93% overlap. When
the 6551 transcripts were instead stratified by PBRM1 mutation
status, widespread intron retention was not observed (Fig. 3B),
suggesting that this effect is specific to tumors with H3K36me3
deficiency. Many of the affected genes are part of recognized can-
cer-associated pathways, including known tumor suppressors (e.g.,
MET, PTEN, and TP53), genes in the DNA repair pathway (e.g., ATR,
RAD50, POLN, and XRCC1), and cell cycle regulators (e.g., CCNB1
Figure 3. H3K36me3 deficiency is associated with intron retention. Intron retention scores for se-
lected genes (Supplemental Fig. S1C) were compared between (A) H3K36me3-deficient tumors and
H3K36me3-normal tumors, and (B) PBRM1-mutant and PBRM1-normal tumors. (C ) Example genes
exhibiting increased intron retention in H3K36me3-deficient tumors (top, PPP2CB; bottom, COX6C).
Intron retention scores, genic coverage (calculated with both intron and exon reads), and exonic
coverage (calculated only with exonic reads) are provided for two H3K36me3-deficient tumors (red)
and two H3K36me3-normal tumors (black).
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and CCND3), as well as numerous receptors and protein kinases
(e.g., BRAF, EGFR, PIK3CA, and TGFBR3) (Supplemental Fig. S8).
Widespread RNA processing defects linked with SETD2
mutations persist in the mature RNA pool and are marked
by altered chromatin accessibility
To test whether observed changes in the pre-mRNA messages
persist into mature polyadenylated RNA, we analyzed TCGA RNA-
seq data derived from poly(A)+ mRNA isolated from a large cohort
(n = 416) of ccRCC tumors. Applying a gene-model-independent
algorithm for read mapping and transcript prediction (Singh et al.
2011), we observed that SETD2-mutant tumors exhibited signifi-
cant alterations in transcript processing (3929 transcripts) (Fig.
4A,B). Alterations included intron retention (12% of altered tran-
scripts) (Supplemental Figs. S1B, S9), variation in exon utilization
(66% of altered transcripts) (Fig. 4B,C; Supplemental S10), and
differences in transcriptional start and termination site usage (22%
Figure 4. Widespread RNA processing defects linked with SETD2 mutations persist in the mature RNA pool and are marked by altered chromatin
accessibility. (A) Splicing differences (see Methods) between SETD2-mutant and SETD2-normal tumors (red) compared with a permuted control (blue) are
plotted as a cumulative distribution function. (B) Significance of the difference in ratios between SETD2-mutant and SETD2-normal tumors (x-axis) plotted
against the scrambled control (y-axis). Points are colored by the class of RNA processing aberrancy. (Gray box) Significance (P = 0.01) in the SETD2-
mutant–normal comparison, but not significant in the control comparison. The percentages of significant differences in transcript processing are also
presented. (C ) Schematic of AP2A1 splicing. Exon skipping was represented as the ratio of included exon coverage to the sum of the exon and the spliced
form. The skipped exon ratio is provided for SETD2-mutant tumors (red) and SETD2-normal tumors (black). (D) Quantitative PCR across two USH1C alter-
native exon utilization sites identified by RNA-seq for three SETD2-normal tumors (black) and two SETD2-mutant tumors (red). Error bars represent standard
error. (E) FAIRE signal plotted around the exon start (63 kb) of misspliced exons (left), random internal exon starts (middle), and random genic positions (right)




of altered transcripts). We also observed the generation of pre-
viously unannotated splice isoforms, which we validated by
quantitative PCR in independent tumor samples (Fig. 4D). Aber-
rancies in RNA processing were detected more frequently in highly
expressed genes (Supplemental Fig. S11A). Low-abundance mes-
sages may preclude the detection of differences in transcript pro-
cessing. However, overall expression of genes exhibiting defects in
RNA processing was comparable between SETD2-mutant and
SETD2-normal tumors (Supplemental Fig. S11B).
Since H3K36me3 preferentially marks well-positioned exonic
nucleosomes (Edmunds et al. 2008; Kolasinska-Zwierz et al. 2009;
Schwartz et al. 2009), we analyzed chromatin accessibility around
the intron–exon boundary of misspliced exons. H3K36me3-nor-
mal tumors demonstrated an expected reduction of FAIRE signal
immediately downstream from intron/exon junctions as well as
a concomitant enrichment in H3K36me3 (from ChIP-seq in nor-
mal kidney), indicative of a well-positioned exonic nucleosome
(Fig. 4E, left), corroborating previous reports (Kolasinska-Zwierz
et al. 2009). Strikingly, in H3K36me3-deficient tumors, evidence of
the exonic nucleosome was lost, and a dramatic increase in chro-
matin accessibility was observed immediately upstream (50 bp) of
the intron/exon junction (Fig. 4E, left, red line). This pattern was
also evident, although less pronounced, at internal exon start sites
of random genes (Fig. 4E, middle) but completely absent at random
genic positions (Fig. 4E, right). Changes in chromatin accessibility
even at internal exons chosen regardless of whether they exhibited
a splicing defect may indicate a more widespread defect that may
not always result in detectable variation in splicing. These data
demonstrate the ability to detect subtle variations in chromatin
organization in primary human tumors and link H3K36me3 loss
with alterations in chromatin accessibility at exons.
Discussion
To identify the genomic consequences of mutated chromatin
regulators, we modified and applied FAIRE-seq to a large cohort of
primary kidney tumors. Using an unbiased approach, we identified
variation in chromatin accessibility distinguishing tumors from
normal kidney. Tumor-specific open chromatin corresponded to
HIF-targeted sites and was linked to genes involved in the hypoxia
response. This result reflects the well-studied association of ccRCC
development with VHL inactivation and HIF stabilization. These
data also serve to validate the use of FAIRE in primary tumors to
detect biologically meaningful pathways.
We then associated variation in chromatin accessibility with
mutations in chromatin regulators. Focusing on SETD2, we ob-
served widespread increases in chromatin accessibility, especially
in gene bodies typically harboring H3K36me3 in normal kidney
tissue. A recent report suggested that SETD2 silencing in cultured
cells results in alternative internal transcriptional start sites
(Carvalho et al. 2013), akin to cryptic initiation observed in yeast
(Carrozza et al. 2005; Lickwar et al. 2009). Our data using human
tumor specimens support a more diverse model for transcriptional
defects, including retention of introns, missplicing of exons, and
usage of alternative transcriptional start or end sites. These defects
were widespread, affecting nearly 25% of all expressed genes, and
defects were more common in highly transcribed genes.
Moreover, we found a surprising increase in chromatin ac-
cessibility immediately upstream (50 bp) of misspliced exons in
SETD2-mutated tumors. This result suggests a mechanism by which
the altered inclusion of the downstream exon is related to nucle-
osome positioning over the exon itself as well as the adjacent up-
stream nucleosome. Nucleosome positioning and histone modi-
fications (including H3K36me3) are known to regulate multiple
processes involved with splicing, including changes in the speed or
pausing of RNA polymerase (Kadener et al. 2001; Howe et al. 2003;
Batsche et al. 2006; Kornblihtt 2007; Munoz et al. 2009), and the
ability for splicing machinery to appropriately recognize the splice
donor and acceptor. Our finding also suggests that the positioning
of this upstream nucleosome may be related to trimethylation of
H3K36 on the exonic nucleosome. In Saccharomyces cerevisiae, loss
of Set2 leads to destabilization of nucleosomes through hyper-
acetylation of gene bodies and cryptic transcriptional initiation
(Carrozza et al. 2005; Lickwar et al. 2009). Since hyperacetylation
was not observed following SETD2 silencing (Edmunds et al.
2008), the increased chromatin accessibility we observed over gene
bodies may therefore represent nucleosome destabilization in a
hyperacetylation-independent manner. Although our results di-
rectly link SETD2 mutation and H3K36 trimethylation to chro-
matin accessibility, studies that specifically examine nucleosome
positioning and histone modification will be necessary to fully
investigate this potential mechanism.
Although our data associate SETD2 mutations/H3K36me3
deficiency with aberrant RNA processing, exactly how this dysre-
gulation contributes to tumorigenesis remains unknown. A signifi-
cant fraction of the deregulated transcripts include known tumor
suppressors, DNA damage response proteins, and kinases. Strik-
ingly, 58% of genes with altered splicing patterns (Fig. 4A,B) en-
code annotated phosphoproteins (P = 7.3 3 10109), representing
an enrichment exceeding that of genes annotated as having al-
ternate splice isoforms (P = 2 3 1060), a finding also observed in
genes exhibiting retained introns (Supplemental Figs. S8, S12).
Alterations in the abundance, stability, or splicing of RNA could
induce changes in the phosphoproteome and disrupt normal cel-
lular signaling and growth checkpoints, leading to tumorigenesis.
Deregulated signaling as well as transcriptional defects provide
numerous putative targets for therapeutic exploitation. Addition-
ally, the application of FAIRE, or IHC for H3K36 trimethylation,
could enable the classification of clinical specimens into func-
tional tumor subtypes.
This study advances our understanding of the relationship
between genetic alterations affecting chromatin organization
and alterations in transcription. RNA processing defects in a large
fraction of expressed genes, many of which are tumor suppressors
critical for cellular function, may be a common phenotype of
many cancers. Comprehensive mapping of the chromatin land-
scape in primary tumors offers a new tool for understanding the
functional consequences of chromatin modifier mutations in hu-
man disease.
Methods
Formaldehyde-assisted isolation of regulatory elements
(FAIRE) and hierarchical clustering of differentially
open chromatin
FAIRE was performed as previously described (Simon et al. 2012).
Sequencing was performed using 36- or 50-bp single-end reads
(Illumina GA IIx or HiSeq 2000). Reads were filtered using TagDust
(Lassmann et al. 2009) and aligned to the reference human ge-
nome (hg19) with Bowtie (Li and Durbin 2009) using default pa-
rameters. Reads were counted in 500-bp sliding windows across the
genome, normalized for sequencing depth, and adjusted for batch
effects using Principal Components Analysis (PCA). One outlier
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normal kidney sample was removed at this step, and all normal
kidney samples were removed for subsequent tumor-only analy-
ses. For clustering analyses, only windows with sufficient se-
quencing depth (row average > 0.25) were retained; groups were
compared using one- or two-sided t-tests (P < 0.01), clustered and
plotted (Saldanha 2004). Feature intersections were computed us-
ing BEDTools (Quinlan and Hall 2010).
Reprocessing of HIF1A, HIF2A, and ARNT ChIP-seq data
ChIP-seq reads for HIF1A, HIF2A, and ARNT (Schodel et al. 2011)
were filtered using TagDust (Lassmann et al. 2009) and aligned to
the reference human genome (hg19) using Bowtie (Li and Durbin
2009) requiring unique read placement. Binding sites for HIF1A
and HIF2A were identified using MACS (Feng et al. 2012), with
a shift-size of 250 bp and significant to q < 0.05.
Ontologies associated with differentially open chromatin
Regions from Clusters 1–3 were associated with Gene Ontologies
using GREAT (McLean et al. 2010) using all possible 500-bp win-
dows as background. The top five ontologies with q < 1 3 105 were
presented; full Gene Ontology associations are supplied in Sup-
plemental Figure S3.
Motif analysis
Significantly overenriched known transcription factor (TF) motifs
were identified using HOMER (Heinz et al. 2010). The 500-bp
flanking region was used as local background. Only those TF motifs
whose enrichment over background exceeded 2.5-fold were pres-
ent in at least 10% of the target sequence, and q < 0.0001 were
presented in Figure 1D. Highly similar entries were merged.
SureSelect custom capture and mutation calling
Genotyping was performed using the SureSelect XT Custom Cap-
ture (Agilent). Multiplexing was achieved using TruSeq adapters
(Illumina); samples were pooled prior to the capture and amplified
post-capture using TruSeq PCR primers (Illumina). Blocking re-
agents were replaced with water to avoid cross-reactivity. Se-
quencing was performed using 50-bp paired-end reads (Illumina
HiSeq 2000). Reads were aligned to the reference human genome
(hg19) using BWA (Li and Durbin 2009). Genes were sequenced to
an average coverage of 2003 with 85% of the target sequenced to
least at 503. Genotypes were determined using the Genome Analysis
Toolkit (GATK) (McKenna et al. 2010) ‘‘Better’’ protocol. Only high-
confidence (quality score >100) variants predicted to have high or
moderate severity and not reported in dbSNP (v129) were considered.
Histone methylation ChIP-seq and data processing
ChIP for H3K36me3 and input DNA from normal kidney was se-
quenced on the Illumina Genome Analyzer II. Reads were aligned
to the reference genome (hg19) using Bowtie requiring unique
alignment. H3K36me3 sites were called first using ZINBA (Rashid
et al. 2011), then merged to call broader domains by merging
nearby sites using Galaxy (Goecks et al. 2010); two or more sites
within 5 kb were merged. The average H3K36me3 signal across
gene bodies was plotted using CEAS (Shin et al. 2009).
Feature overlap permutations
Significance of overlap between sites of differentially open chro-
matin associated with SETD2 or PBRM1 mutations and H3K36me3
sites was determined by permutation. First, the overlap between
the actual set of significant windows and histone methylation was
computed. Then the same number of randomly selected windows
from the full list (regardless of significance) was selected 1000
times, and an empirical P-value was determined by counting the
number of times the overlap of the permuted set exceeded that of
the actual set.
Tissue microarray construction and immunohistochemistry
Tissue microarrays (TMAs) were constructed from formalin-fixed,
paraffin-embedded tumor blocks from 69 ccRCC tumors and 11
matched normal kidneys collected at the time of nephrectomy. He-
matoxylin and eosin–stained slides were reviewed to identify a target
area of ccRCC histology in each tissue block. TMAs were then
constructed using 0.6-mm cores on the manual tissue microarrayer
(Beecher Instruments). Tumor and normal samples were represented
in triplicate. Sequential 4-mm slides were cut from each TMA.
Immunohistochemical (IHC) staining of H3K36me3, histone
H3, and SETD2 was performed (Bond Autostainer, Leica Micro-
systems, Inc.) according to the manufacturer’s protocol. Antigen
retrieval for H3K36me3, SETD2, and histone H3 was performed for
30 min in citrate buffer (pH 6.0) (Bond #AR9961) and hydrated
with Bond wash buffer (AR9590). Slides were incubated with
H3K36me3 antibody (Abcam, ab9050, dilution 1:2000) or histone
H3 (courtesy of the Strahl laboratory, dilution 1:5000) or SETD2
(Abcam, ab31358, 1:200) for 1 h at room temperature. Antibody
detection was performed (Bond Polymer Refine Detection System,
DS9800) followed by image acquisition (ScanScope CS, Aperio
Technologies).
Quantification of H3K36me3, SETD2, and histone H3 was
performed independently by two reviewers who were blinded to
the tissue identity. The percentage of tumor cells with positive
nuclei was determined by evaluating the entire core for each
sample. The degree of H3K36me3 or SETD2 staining was averaged
across triplicate samples and normalized to total H3 to correct for
differences in cell number. Using the minimum value of normal-
ized H3K36me3 in normal kidney as a cutoff, tumors were strati-
fied as either ‘‘H3K36me3-normal’’ or ‘‘H3K36me3-deficient’’ for
subsequent analyses. Five additional tumors (not represented on
the tissue microarray) were similarly assessed by immunohisto-
chemistry and classified as ‘‘H3K36me3-deficient’’ (three tumors)
or ‘‘H3K36me3-normal’’ (two tumors).
Intron retention estimates by RNA-seq
Total RNA was isolated from tumors (miRNeasy, Qiagen) and val-
idated to have a median RNA Integrity Numbers (RIN) of 8.6
(minimum 6.8) using a Bioanalyzer (Agilent). Ribosomal RNA was
depleted (RiboMinus, Invitrogen) and RNA was fragmented (RNA
Fragmentation Reagents, Ambion). cDNA was generated (Super-
Script II, Invitrogen) by random priming followed by second
strand synthesis (DNA polymerase I, Enzymatics) and purified
(PCR purification kit, Qiagen). Libraries were prepared according to
the manufacturer’s specifications (Illumina). Sequencing was per-
formed using 50-bp single-end reads (Illumina HiSeq 2000). Reads
were aligned to the reference human genome (hg19) using TopHat
(Trapnell et al. 2009), and gene expression was estimated by cal-
culating RPKM, analyzing only exonic reads. Intron retention













Total RNA extracted from patient tumors (Qiagen miRNeasy) was
either rRNA-depleted (RiboMinus, Invitrogen) or poly(A)-selected
(Oligotex mRNA Mini Kit, Qiagen). RNA was reverse-transcribed by
random priming (SuperScript II Reverse Transcriptase, Invitrogen),
and cDNA was quantified by PCR and normalized to ABCF1
(Maxima SYBR Green/ROX qPCR Master Mix, Thermo Fisher Sci-
entific; 7900HT Fast Real-Time PCR System, Applied Biosystems)
(see Table 1).
Differential splicing analysis
RNA-seq reads were aligned to the human reference genome using
MapSplice (Wang et al. 2010). For each gene, a splicing graph was
created as previously described (Singh et al. 2011). Each exon and
splicing event was represented as an edge, and splice junctions
as nodes. We computed a ‘‘splicing fraction’’ of each edge as the
fraction of RNA-seq coverage in that edge divided by the total
coverage of all edges sharing one node of that edge. Only edges
with coverage exceeding 5 reads and genes with multiple isoforms
(13,879 genes) were considered. The node exhibiting the largest
difference between SETD2 mutant and normal tumors was deter-
mined by comparing the median of each group. As a control, we
created random groups of tumors of the same sizes. Splicing dif-
ferences between SETD2-mutant and normal tumors were com-
pared with that of the control group by a Kruskal–Wallis one-way
analysis of variance test. The skipped exon ratio was computed as
the ratio of coverage of the included exon, and the sum of cover-
ages of the included exon and the skipping splice.
Data acquisition
TCGA data were accessed with authorization. Nephrectomy spec-
imens were collected under institutional IRB-approved protocols.
Data access
Sequencing data and mutational analysis files have been submitted
to EMBL-EBI ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) un-
der accession number E-MTAB-1936.
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